A computer readable text file, entitled “SequenceListing.txt,” created on or about Mar. 23, 2017 with a file size of about 21 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
1. Field of the Invention
The present invention relates to a modified TXNIP (thioredoxin-interacting protein) protein, a method for preparing the modified TXNIP protein, a polynucleotide encoding the modified protein, an expression vector comprising the polynucleotide, a transformant introduced with the expression vector, a method for crystallizing a modified TRX(thioredoxin)-TXNIP complex using the modified TXNIP protein, and a method for screening a substance regulating interaction between TRX and TXNIP, an inhibitor of TRX activity, and a substance regulating TXNIP function, using the crystal structure of the TRX-TXNIP complex mutein.
2. Description of the Related Art
TRX, which is up-regulated in many cancers, is involved in a wide range of cell signaling processes comprising cellular immune response, in response to a variety of oxidative stresses, and thus TRX is an important protein that has received much attention from the world's major pharmaceutical companies as an attractive target for anticancer drugs (Powis, G. et al., 2007 Current Opinion in Pharmacology 7:392, Mukherjee, A. et al., 2008 The British Journal of Radiology 81:S57). TXNIP, the only currently known endogenous inhibitor of TRX, inhibits interaction between TRX and a range of proteins involved in cell signaling as well as redox-potential activity of TRX. Therefore, studies have been actively conducted on TRX-TXNIP roles in cancers and metabolic diseases (Schulze, P. C. et al., 2004 J Biol Chem 279:30369, Dunn, L. L. et al., 2010 Arteriosclerosis, Thrombosis, and Vascular Biology 30:2089, Spindel, O. N. et al., 2012 Antioxidants & Redox Signaling 16:587), which is supported by the experimental results that TXNIP is strongly down-regulated in a variety of tumor cells and tissues (Shin, K. H. et al., 2008 Biochem Biophys Res Commun 372:880), and TXNIP knockout mice have an increased incidence of hepatocellular carcinoma (Sheth, S. S. et al., 2006 Oncogene 25:3528). The function of TXNIP as the tumor suppressor inhibiting TRX activity is well-known in the research related to inhibition of TRX-ASK1 (apoptosis signal-regulating kinase 1) interaction by TXNIP. That is, TXNIP-TRX interaction inhibits TRX-ASK1 interaction, leading to increased levels of reactive oxygen species (ROS) and promotion of cell apoptosis by ASK1 (Matsuoka, S. et al., 2008 Cancer Science 99:2485).
In addition to its function as an endogenous inhibitor of TRX, TXNIP is correlated with glucose levels (Muoio, D. M. 2007 Cell Metabolism 5:412, Parikh, H. et al., 2007 PLoS Medicine 4:2158). Glucose stimulates TXNIP transcription through a carbohydrate-response element present in the TXNIP promoter (Minn, A. H. et al., 2005 Endocrinology 146:2397) and its association with transcription factors MLX (max-like protein X) and MondoA (Stoltzman, C. A. et al., 2008 Proc Natl Acad Sci USA 105:6912). An elevated level of TXNIP has led to a reduction in the number of pancreatic beta-cells, insulin secretion, and peripheral glucose uptake (Parikh, H. et al., 2007 PLoS Medicine 4:2158, 23). By contrast, TXNIP deficiency protected against beta-cell apoptosis, and enhanced insulin sensitivity (Yoshihara, E. et al., 2010 Nature Communications 1:127, Chen, J. et al., 2008 FASEB Journal 22:3581). Despite considerable efforts to identify TXNIP characteristics and molecular mechanism of TRX regulation by TXNIP which are involved in metabolic diseases as well as cancers, understanding of TXNIP and regulation mechanism of TXNIP-TRX has reached a limit, because of a lack of their structural information.
Recent studies change their approach from a random approach to exploration of a number of anticancer drug candidates and therapeutic candidates to a new approach to development of effective therapeutic agents by exploration of target proteins, investigation of structure and reaction mechanism of the target proteins, and design and development of drug candidates through more efficient and scientific protein engineering. To design and develop drug candidates, investigation of their three-dimensional structures is essential. To investigate the three-dimensional structures, the priority is to acquire the protein in a stable form. However, the three-dimensional structure of the TXNIP protein, for all its importance, has not been revealed yet, because the TXNIP protein is a redox protein containing 11 cysteines, making it difficult to handle during production.
Accordingly, the present inventors have made many efforts to investigate the three-dimensional structure of the TXNIP protein. As a result, the present inventors have established a method for preparing a stable TRX-TXNIP complex having a purity of 90% or more, through various types of engineering, and they prepared a complex crystal of a TRX protein and a modified TXNIP protein, activity of which has no significant difference from that of the wild-type and demonstrated interaction between TRX and TXNIP at the protein level. Consequently, they have found that a substance capable of regulating the activities of TRX and TXNIP or interaction there between can be developed, based on the protein structure, thereby completing the present invention.
An object of the present invention is to provide a method for crystallizing a modified TRX-TXNIP complex, comprising a modified TXNIP protein and a modified TRX protein.
Another object of the present invention is to provide a crystal of the modified TXNIP protein, and a crystal of the modified TRX-TXNIP complex.
Still another object of the present invention is to provide a modified TXNIP protein, a polynucleotide encoding the protein, an expression vector comprising the polynucleotide, and a transformant introduced with the expression vector.
Still another object of the present invention is to provide a method for preparing the modified TXNIP protein.
Still another object of the present invention is to provide a method for screening a substance regulating interaction between TRX and TXNIP, by utilizing the three-dimensional structure of the modified TXNIP protein or the modified TRX-TXNIP complex.
Still another object of the present invention is to provide a method for screening an inhibitor of TRX activity, by utilizing the three-dimensional structure of the modified TXNIP protein or the modified TRX-TXNIP complex.
Still another object of the present invention is to provide a method for screening a substance regulating TXNIP function, by utilizing the three-dimensional structure of the modified TXNIP protein or the modified TRX-TXNIP complex.
TRX(C73A)-T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) complex was incubated with 100 mM DTT and subjected to size exclusion chromatography to isolate T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) from remained protein complex and TRX. The fractions containing T-TXNIP (C36S/C49S/C120S/C170S/C205S/C267S) were collected and dialyzed against 50 mM Tris-HCl (pH 8.0), 500 mM NaCl and 10% glycerol to induce the formation of disulfide bonds between TXNIP molecules;
In one aspect, the present invention provides a method for crystallizing a modified TRX-TXNIP complex comprising a modified TXNIP protein and a modified TRX protein.
Specifically, the method for crystallizing the modified TRX-TXNIP complex comprises the steps of: (a) co-expressing the modified TXNIP protein, which is prepared by deleting 2 amino acids at the N-terminus and 74 amino acids at the C-terminus, and substituting serines (Ser) for cysteines (Cys) at positions 170, 205, and 267 in an amino acid sequence of SEQ ID NO: 1 of TXNIP protein, and the modified TRX protein represented by SEQ ID NO: 3; and (b) crystallizing the modified TXNIP protein and the modified TRX protein; but is not limited thereto. The modified TXNIP protein may be a modified protein further comprising a substitution of serine for cysteine at position 120, but is not limited thereto.
In the crystallizing method, Step (a) may include a step of purifying the expressed proteins, and purification of the proteins may be conducted by a known purification method such as affinity chromatography, etc.
As used herein, the term “TRX protein” is a redox-active protein which functions as a defense protein in response to a variety of oxidative stresses and plays pivotal roles in intra- and extracellular signaling pathways. With respect to the objects of the present invention, TRX means a protein that interacts with TXNIP, but is not limited thereto. TRX is preferably human TRX, but is not limited thereto. The amino acid sequence and nucleotide sequence of the TRX protein can be obtained from the known database such as NCBI GenBank, and preferably, an amino acid sequence of SEQ ID NO: 2 and a nucleotide sequence of SEQ ID NO: 10, but is not limited thereto.
As used herein, the term “modified TRX protein” means a protein prepared by substitution, insertion, deletion, or alteration of one or more amino acids in the wild-type TRX protein. With respect to the objects of the present invention, modified TRX protein means a protein modified in order to prevent further reactions after interaction with TXNIP, but is not limited thereto. The modified TRX protein comprises any modified TRX protein without limitation, as long as it is a soluble, or a soluble and crystalline protein, but is not limited thereto. The modified TRX protein is preferably a protein prepared by substitution of alanine (Ala) for cysteine (Cys) at position 35 in the wild-type TRX protein, but is not limited thereto. In the present invention, TRX protein having a substitution of alanine for cysteine at position 35 was designated as TRX(C35A)(SEQ ID NO:3). This modified TRX protein may be a protein having the amino acid sequence of SEQ ID NO: 3, and it may also be a protein having an amino acid sequence having 70% or more homology, preferably 80% or more homology, more preferably 95% or more homology, or much more preferably 98% or more homology thereto, in which it is apparent that a protein having an amino acid sequence in which a part thereof is deleted, altered, substituted, or added is also included in the scope of the present invention, as long as it substantially has an activity to form a crystal, together with the modified TXNIP protein. In one embodiment of the present invention, a modified TRX protein was prepared by substitution of alanine for cysteine at position 35 in TRX protein having the amino acid sequence of SEQ ID NO: 2, and then used for the preparation of a modified TRX-TXNIP complex crystal, together with the modified TXNIP protein.
As used herein, the term “TXNIP protein” means a protein that is able to interact with TRX protein, and interacts with TRX to inhibit TRX activity. The TXNIP protein acts as a tumor suppressor protein in cancer and its expression is down-regulated in a variety of tumor cells. TXNIP interacts with TRX which is up-regulated in tumor cells to inhibit its activity, thereby exhibiting an anticancer effect, but is not limited thereto. The anticancer activity of TXNIP may be exemplified by an anticancer activity through inhibition of binding between TRX and ASK1, but is not limited thereto. The TXNIP protein may be preferably human TXNIP protein (SEQ ID NO: 1), but is not limited thereto. The amino acid sequence and nucleotide sequence of the TXNIP protein can be obtained from a known database such as NCBI GenBank, and preferably, an amino acid sequence of SEQ ID NO: 1 and a nucleotide sequence of SEQ ID NO: 9.
As used herein, the term “modified TXNIP protein” means a protein prepared by substitution, insertion, deletion or alteration of one or more amino acids in the wild-type TXNIP protein. With respect to the objects of the present invention, the modified TXNIP protein is any protein without limitation, as long as it is able to form a complex with the wild-type or modified TRX protein and has alteration of one or more amino acids in the amino acid sequence encoding the wild-type TXNIP protein. The modified TXNIP protein may be preferably a protein prepared by deletion of 2 amino acids at the N-terminus and 74 amino acids at the C-terminus, and substitution of serines for cysteines at positions 170, 205, and 267 in the wild-type TXNIP protein (e.g. SEQ ID NO: 4 and 5, respectively), but is not limited thereto. Further, the modified TXNIP protein comprises a protein prepared by further substitution of serine for cysteine at position 120, in addition to substitution of serines for cysteines at positions 170, 205, and 267 (e.g. SEQ ID NO: 6). Through the alteration of the length and partial sequences of the wild-type TXNIP protein, the modified TXNIP protein becomes more prone to crystallization than the wild-type TXNIP protein, which could not be crystallized together with TRX protein.
The modified TXNIP protein prepared by deletions of 2 amino acids at the N-terminus and 74 amino acids at the C-terminus in the wild-type TXNIP protein was designated as T-TXNIP, and represented by SEQ ID NO: 4.
Further, the modified TXNIP protein prepared by substitutions of serines for cysteines at positions 170, 205, and 267 based on the wild-type TXNIP protein represented by the amino acid sequence of SEQ ID NO: 1 in T-TXNIP was designated as T-TXNIP(C170S/C205S/C267S), and represented by SEQ ID NO: 5.
Furthermore, the modified TXNIP protein prepared by further substitution of serine for cysteine at position 120 in T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) was designated as T-TXNIP(C120S/C170S/C205S/C267S), and represented by SEQ ID NO: 6.
In one embodiment of the present invention, in order to prepare a crystal of the modified TXNIP protein and TRX(C35A)(SEQ ID NO:3) complex, T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) were used as the modified TXNIP protein, respectively. Like the wild-type TXNIP protein, the T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) proteins effectively inhibited the activity of TRX protein, suggesting that their activities are not affected by the substitution of serines for cysteine residues (
As used herein, the term “TRX-TXNIP complex” means a complex formed by interaction between TRX protein and TXNIP protein. Preferably, it may be a complex formed through an intermolecular disulfide bond between the cysteine residue (Cys32) at position 32 of TRX protein and the cysteine residue (Cys247) at position 247 of TXNIP protein, but is not limited thereto.
As used herein the term “modified TRX-TXNIP complex” means a protein complex formed by interaction between the modified TRX protein and the modified TXNIP protein. The modified TRX-TXNIP complex means a complex formed through an intermolecular disulfide bond between the cysteine residue at position 32 of the modified TRX protein and the cysteine residue at position 247 of the modified TXNIP protein, but is not limited thereto. The modified TRX-TXNIP complex may be preferably a modified complex formed by interaction between TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5), or a modified complex formed by interaction between TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C120S/C170S/C205S/C267S) (SEQ ID NO: 6), but is not limited thereto. The modified TRX-TXNIP complex of the present invention is formed by interaction between the modified TXNIP protein and the modified TRX protein, in which the modified TXNIP protein can be easily crystallized due to modification of the TXNIP protein, of which crystallization trials have been unsuccessful, without affecting its activity. The modified TRX-TXNIP complex is a protein capable of forming its crystal structure. Thus, it provides an advantage in that the interaction between TRX and TXNIP can be analyzed through its three-dimensional structure. In one embodiment of the present invention, the modified TRX-TXNIP complex was used to prepare two crystals, COM1 (TRX(C35A) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6)) and COM2 (TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C170S/C205S/C267S)(SEq ID NO: 5)). Their structures were examined (in Example 6, Experimental Example 1 and
As used herein, the term “interaction between TRX protein and TXNIP protein” means interaction by a disulfide bond between Cys32 of TRX protein and Cys247 of TXNIP protein, but is not limited thereto. The interaction between TRX protein and TXNIP protein, particularly, the β18 strand of TXNIP in combination with β15 is a critical component of the interaction, and intermolecular backbone-backbone interactions between TRX and the β18 strand of T-TXNIP contributes to stabilization of the disulfide bond between C32 of TRX and C247 of TXNIP. Further, Arg251 (Arginine, R) of TXNIP protein forms a salt bridge with Asp60 (aspartic acid, D) of TRX protein, which further contributes to stabilization of the interaction (
In the present invention, the mechanism by which interaction between TRX protein and TXNIP protein is regulated, was demonstrated by using the crystal structure investigated in the present invention. In detail, the interaction between TRX protein and TXNIP protein is caused by disulfide bond switching. A head-to-tail interprotomer disulfide bond between Cys63 and Cys247 of TXNIP is present in TXNIP proteins, and when TRX approaches and interacts with TXNIP, disruption of the interprotomer disulfide bond occurs, and a disulfide bond between TRX Cys32 and TXNIP Cys247 is formed, and a disulfide bond between Cys63 and Cys190 in the TXNIP protein is formed, leading to S-shaped conformation of TXNIP protein (
The crystallization method preferably comprises the step of co-expressing the modified TRX protein and the modified TXNIP protein, but is not limited thereto.
Since TXNIP protein is not expressed as a soluble protein without TRX protein, co-expression of the modified TRX protein and the modified TXNIP protein is preferred in order to prepare the modified TRX-TXNIP complex in soluble form. Such co-expression may be performed by expressing them in a single vector, a single cell or separate individual vectors, and the proteins thus expressed may be purified, followed by crystallization. In one embodiment of the present invention, a two-promoter vector system capable of co-expressing the modified TRX protein and the modified TXNIP protein was used to prepare a vector comprising polynucleotides encoding each of the two proteins in a single vector (Example 1).
As used herein, the phrase “expressed in soluble form” means that a protein having low solubility is expressed in soluble form. Expression in soluble form is a prerequisite for crystallization of a protein. Most proteins form crystals readily when they are in water-soluble form, and therefore, this step is required for the subsequent crystallization step.
As used herein, the phrase “allowing crystallization” or “having crystallinity” means that, in order to prepare a protein in a form suitable for X-ray analysis of its tertiary structure, mutations are introduced into the protein molecule so as to form solid particles having a uniform shape and size from a uniform liquid or to further stabilize the crystal of the protein. The three-dimensional structure of a protein is very important for the understanding of in vivo actions of the protein and development of therapeutic drugs. That is, since an understanding of the arrangement and three-dimensional structure of atoms constituting a protein as a macromolecule makes it possible to analyze the three-dimensional structure of the modified TRX-TXNIP complex and to provide a platform for development of new drugs for inhibiting interaction between TRX protein and TXNIP protein, it is a common issue in biological and medical fields. However, it was very difficult to demonstrate the three-dimensional structure of the TRX-TXNIP complex. A crystal structure of the TRX-TXNIP complex should be first prepared in order to analyze the three-dimensional structure of the complex, and the protein complex should be prepared in soluble form in order to prepare its stable crystal structure. In order to acquire such protein, the present inventors expressed both the modified TRX protein and the modified TXNIP protein, and prepared modified TRX and TXNIP proteins by substitution of cysteine residues in the amino acid sequence(s) of TRX or/and TXNIP protein, and then prepared the modified TRX-TXNIP complex which serves as a stable TRX-TXNIP complex, using the modified proteins.
The crystallization of Step (b) may be carried out by a variety of known crystallization methods, preferably, by a vapor diffusion method. The vapor diffusion method may be a sitting drop vapor diffusion method or a hanging-drop vapor diffusion method, and more preferably, the sitting drop vapor diffusion method, but is not limited thereto.
As used herein, the term “sitting drop vapor diffusion method” refers to a crystallization method in which, when a microdrop of mother liquor and a much larger reservoir solution exist separately in a closed system, transport of either water or other volatile agent occurs between them, leading to a supersaturated state of protein, and in such a thermodynamically metastable state, proteins are precipitated depending on the precipitant. While the protein precipitation slowly occurs, stable crystals are formed and the precipitant functions to lower the solubility of the concentrated protein solution, and proteins congregate to form crystals in order to reduce an adsorption layer around protein molecules. The reservoir solution contains a mixture of the precipitant, buffer, salt, and detergent at different concentrations. Droplets are usually formed by mixing the protein solution with the reservoir solution of various conditions at a ratio of 1:1, and the droplets thus formed are placed on a microbridge, and sealed. At this time, there is a difference in the concentration between the proteins in the droplets and the reservoir solution, and thus the proteins do not begin as crystals. They are equilibrated while sealed, and crystals are formed under the specific conditions by the above described principle. In the sitting drop vapor diffusion method, the type and proper concentration of the salt, the buffer and the surfactant as well as the precipitant in the reservoir solution, pH of the solution, and the experimental temperature vary depending on the type of protein, and in some cases, they become very important factors in crystal formation of proteins.
As used herein, the term “hanging-drop vapor diffusion method” is a protein crystallization method, which provides crystals having a size sufficient for protein structural analysis. In the hanging-drop vapor diffusion method, a reagent containing a sample and a pure liquid reagent are placed on the top of the reservoir under vapor equilibration. To achieve equilibrium of the sample having a lower reagent concentration than the reservoir, water contained in the sample eventually ends up in the reservoir. Water contained in the sample is removed until the concentration is approximately the same as that in the liquid reagent, and finally, protein crystals reaching the equilibration can be obtained.
In one embodiment of the present invention, the sitting drop vapor diffusion method was used to obtain N-TXNIP, COM1, and COM2 crystals (Example 6).
In another aspect, the present invention provides a crystal of the modified TXNIP protein or the modified TRX-TXNIP complex.
The modified TXNIP protein is the same as described above. The modified TXNIP protein is preferably N-TXNIP(K5A/K6A) protein (SEQ ID NO: 8), and the modified TRX-TXNIP complex is TRX(C35A)(SEQ ID NO:3)-T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complex (COM1) and TRX(C35A)(SEQ ID NO:3)-T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) complex (COM2), but are not limited thereto.
There are many different methods for analyzing a protein's crystal structure, and two main methods are NMR spectroscopy and X-ray crystallography. NMR Spectroscopy is based on the principle of predicting a distance between particular atoms in a molecule by analyzing signal changes due to chemical factor which can be detected in the NMR spectrum of a molecule. Data of the chemical shift obtained by the NMR test is analyzed to obtain a set of the distances between labeled atoms in one protein, and a model or a set of models satisfying information about all distances determined by the experiment is produced. Thus, there is a disadvantage of requiring collection and analysis of a large amount of data. Meanwhile, X-ray crystallography is based on the principle of obtaining the result by analyzing x-ray scattered by electron cloud surrounding an atom of the crystal in an x-ray generator. X-ray diffraction patterns from protein crystals are regular because the individual protein molecules are arranged in a regular lattice. Based on this principle, X-ray crystallography is a method of analyzing a protein structure by producing an electron density map of the protein using x-ray scattered and reflected from the protein crystals. However, there is a disadvantage of requiring pure protein samples and protein crystallization. In the present invention, the TXNIP protein of which crystallization trials have been unsuccessful was properly modified to prepare crystals of N-TXNIP protein, COM1, and COM2.
In the present invention, to provide three-dimensional crystal structures of N-TXNIP(K5A/K6A) protein (SEQ ID NO: 8), COM1, and COM2, diffraction patterns were obtained using an x-ray image plate, and phase information was obtained by multiple anomalous dispersion (MAD) using Se-Met (selenium-methionine). An electron density map was obtained from the x-ray diffraction patterns and phase information, and atomic coordinates were derived therefrom so as to obtain the three-dimensional structures. The crystal of N-TXNIP(K5A/K6A) protein (SEQ ID NO: 8) of the present invention is preferably a crystal having an amino acid sequence represented by SEQ ID NO: 8 and having a space group of P212121 and a unit-cell dimension of a=37.43 Å, b=56.62 Å, and c=67.66 Å, and α=β=γ=90°, but is not limited thereto (Table 8). The N-TXNIP(K5A/K6A) protein (SEQ ID NO: 8) has atomic coordinates shown in Table 9.
Further, the crystal of COM1 of the present invention is preferably a crystal of complex of the modified TXNIP protein represented by SEQ ID NO: 6 and the modified TRX protein represented by SEQ ID NO: 3, and having a space group of P21 and a unit-cell dimension of a=80.14 Å, b=64.02 Å, c=88.30 Å, α=γ=90° and β=91.28°, but is not limited thereto (Table 8). The COM1 complex has atomic coordinates shown in Table 10, and the atomic coordinates and the structure-factor amplitudes thereof were deposited in PDB (Protein Data Bank) under accession code of 4LL1.
The crystal of COM2 of the present invention is preferably a complex crystal of the modified TXNIP protein represented by SEQ ID NO: 5 and the modified TRX protein represented by SEQ ID NO: 3, and having a space group of P21 and a unit-cell dimension of a=79.83 Å, b=64.99 Å, c=88.42 Å, α=γ=90°, and β=90.88°, but is not limited thereto (Table 8). The COM2 complex has atomic coordinates shown in Table 11, and the atomic coordinates and the structure-factor amplitudes thereof were deposited in PDB (Protein Data Bank) under accession code of 4LL4.
As used herein, the term “space group” means the symmetry of a unit cell of a crystal, and combinations of symmetry elements form symmetry groups. This space is used interchangeably with the space group.
As used herein, the term “unit-cell dimension” is also called lattice parameter, and the unit-cell is the simplest minimum repeating unit constituting the space group, and defined by three crystallographic axes, the lengths of the three vectors (a, b, c) and the inter-axial angles (α, β, γ).
The phase information can be obtained by multiple isomorphous replacement, multiwavelength anomalous dispersion, molecular replacement, or the like. First, multiple isomorphous replacement is a technique of obtaining the phase information by replacing crystals with heavy metals, and collecting and analyzing the data. Second, multiwavelength anomalous dispersion is a widely used technique of obtaining phase information by collecting data using the anomalous dispersion at different wavelengths, in which a specific metal or atom in the crystal is used instead of heavy metals. That is, without the need for collecting data of many crystals, data can be easily obtained from one crystal using a selenium atom by replacing the amino acid methionine with selenomethionine (Se-Met) using a molecular biological method. However, this method has a disadvantage in that data should be obtained from a radiation beam. Third, molecular replacement is a method of solving the phase problem from a known similar structure, and it is widely used as the number of known structures is increasing. Data is collected from each structure, and then refinement is conducted to fit our model against the data. This procedure is performed using known programs (CCP4, Coot, Quanta, CNS, etc.), and standardization of each angle, bond length, etc. is required. In this process, a procedure for fitting the model to the obtained electron density map is performed repeatedly by computer and by eye. In the analysis step after refinement of the structure, a lot of information can be derived from the structure with interpretation. In this analysis step, the mechanism of action can be studied, based on the structure. The studies on the correct mechanism of action provide information needed for development of new drugs. Further, the directly related residues can be identified through the structure of the complex of the protein and its regulator, and therefore, important information is provided for the next step for studying the regulator.
In the present invention, phase information of human N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1, and COM2 structures was obtained by multiple anomalous dispersion (MAD), and SOLVE and RESOLVE programs were used for calculation thereof, and COOT and REFMAC5 programs were used for refinement of the structures. The atomic coordinates and the structure-factor amplitudes of N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1, and COM2 thus obtained are shown in Tables 9 to 11, respectively and their three-dimensional structures are shown in
In still another aspect, the present invention provides a modified TXNIP protein, a polynucleotide encoding the modified TXNIP protein, an expression vector comprising the polynucleotide, and a transformant introduced with the expression vector.
The modified TXNIP protein is the same as described above.
The expression vector comprising the polynucleotide encoding the modified TXNIP protein provided in the present invention may be, but is not particularly limited to, a vector capable of replicating and/or expressing the polynucleotide in eukaryotic or prokaryotic cells comprising mammalian cells (e.g., human, monkey, rabbit, rat, hamster, mouse cells, etc.), plant cells, yeast cells, insect cells, or bacteria cells (e.g., E. coli, etc.), preferably, a vector which is operably linked to a suitable promoter to express the polynucleotide in the host cells and comprises at least one selection marker. More preferably, it may be in the form of a phage, a plasmid, a cosmid, a mini-chromosome, a virus, a retrovirus vector to which the polynucleotide is introduced.
The expression vector comprising the polynucleotide encoding the modified TXNIP protein may be an expression vector further comprising a polynucleotide encoding the wild-type or modified TRX protein. Since the modified TXNIP protein is not expressed as a soluble protein without a TRX protein, the expression vector comprising the polynucleotide encoding the modified TXNIP protein may be introduced, together with the expression vector comprising the polynucleotide encoding the wild-type or modified TRX protein, or a single expression vector comprising both the polynucleotides encoding the wild-type or modified TRX protein and the polynucleotide encoding the modified TXNIP protein may be introduced to express both the TRX protein and the modified TXNIP protein.
As used herein, the term “transformant” refers to a host cell transformed with the vector, and means a transformant capable of producing a large amount of soluble, or soluble and crystalline N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1 or COM2 proteins of the present invention, and also comprises a transformant which is introduced with the N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1 or COM2 protein and thus is used to screen candidates for new drug development through NMR, etc, but is not limited thereto. The transformant introduced with the expression vector provided in the present invention may be, but is not particularly limited to, bacterial cells such as E. coli, Streptomyces, Salmonella typhimurium, etc.; yeast cells; fungus cells such as Pichia pastoris; insect cells such as Drosophila, Spodoptera Sf9 cell, etc; animal cells such as CHO, COS, NSO, 293T, Bowes melanoma cells, etc.; or plants cells, which are transformed by introduction of the expression vector.
As used herein, the term “introduction” refers to delivery of the vector comprising the polynucleotide encoding the modified TXNIP protein into a host cell. This introduction may be performed by various methods known in the art, comprising calcium phosphate-DNA coprecipitation, DEAE dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection and protoplast fusion. Further, the term “transfection” means delivery of a desired material into a cell by means of infection using viral particles. In addition, the vector may be introduced into a host cell by gene bombardment. In the present invention, the introduction may be used interchangeably with transformation.
In still another aspect, the present invention provides a method for preparing the modified TXNIP protein.
The modified TXNIP protein is the same as described above.
A method of preparing T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) among the modified TXNIP proteins may include the steps of deleting 2 amino acids at the N-terminus and 74 amino acids at the C-terminus in the amino acid sequence of SEQ ID NO: 1 of the TXNIP protein, and substituting serines (Ser) for cysteines (Cys) at positions 170, 205, and 267 based on the amino acid sequence of SEQ ID NO: 1. Further, a method of preparing T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) among the modified TXNIP proteins may include the steps of deleting 2 amino acids at the N-terminus and 74 amino acids at the C-terminus in the amino acid sequence of SEQ ID NO: 1 of the TXNIP protein, and substituting serines (Ser) for cysteines (Cys) at positions 120, 170, 205, and 267, but is not limited thereto.
Further, a method preparing N-TXNIP(K5A/K6A) (SEQ ID NO: 8) may include the steps of comprising only the amino acids at position 3 to 156 in the amino acid sequence of SEQ ID NO: 1, and substituting alanines for lysines at positions 5 and 6, but is not limited thereto.
In still another aspect, the present invention provides a method for screening a substance candidate regulating the interaction between TRX and TXNIP by utilizing the tertiary structure of the modified TXNIP protein or the modified TRX-TXNIP complex.
Preferably, the method may include: (a) producing or selecting a candidate regulating interaction between TRX and TXNIP using a tertiary structure of N-TXNIP (the N-terminal domain of thioredoxin-interacting protein) having the atomic coordinates shown in Table 9; a tertiary structure of the modified TRX-TXNIP complex having the atomic coordinates shown in Table 10; or a tertiary structure of the modified TRX-TXNIP complex having the atomic coordinates shown in Table 11; and (b) examining whether the candidate produced or selected in Step (a) regulates interaction between TRX and TXNIP.
The modified TXNIP protein and the modified TRX-TXNIP complex are the same as described above.
The modified TXNIP protein is preferably N-TXNIP(K5A/K6A) (SEQ ID NO: 8), and the modified TRX-TXNIP complex is preferably COM1 or COM2, but is not limited thereto. The atomic coordinates of N-TXNIP and the modified TRX-TXNIP complexes can be obtained by atomic coordinates of the proteins shown in Tables 9 to 11. The atomic coordinates of N-TXNIP(K5A/K6A) (SEQ ID NO: 8) is shown in Table 9, the atomic coordinates of COM1 is shown in Table 10, and the atomic coordinates of COM2 is shown in Table 11.
Further, the atomic coordinates for N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1 or COM2 can be stored in media for consecutive use in a calculating apparatus such as a computer. Typically, the coordinates can be stored in media (e.g., floppy disks, hard disks, compact disks, magneto-optical media, or electronic media) useful for storing large amounts of data, such as magnetic or optical media. Those skilled in the structural/computational chemistry are used to selecting the computer, storage media, networking, and another device or technique.
Based on the three-dimensional structure of N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1 or COM2 demonstrated in the present invention, information about various protein sites comprising binding sites can be provided by using computer readable media containing the data of the atomic coordinates and/or three-dimensional structure. Through these procedures, reaction patterns of numerous drug candidates can be predicted without practical experiments, and only the resulting selected substances are subjected to experiments, leading to economic improvement in new drug development.
Further, step (a) of the screening method may include the steps of entering the data of the atomic coordinates for the tertiary structures of the proteins into a computer, together with a proper software program; and obtaining a three-dimensional protein structure for visualization and additional computer manipulation, but is not limited thereto. When the tertiary structure of TXNIP, TRX, or complex thereof is designed using the atomic coordinates shown in Tables 9 to 11, amino acids can be appropriately modified within the scope without causing a large structural change, such as substitution of the amino acids which are the same as in the wild-type for the modification of the wild-type protein, but is not limited thereto.
If all or part of the tertiary structure of the N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1 or COM2 is used, a candidate capable of regulating interaction between TRX and TXNIP can be specifically selected or produced. That is, based on the tertiary structure, a substance capable of regulating the interaction can be designed, and a candidate substance can be selected by examining whether the known substances are able to regulate the interaction. Further, it is known that binding of TXNIP protein to TRX protein inhibits TRX activity. It is also known that TRX protein is up-regulated in tumor cells to promote tumorigenesis. Therefore, the candidates can be determined as anticancer therapeutic agents having anticancer effects on tumors by examining whether the candidates promote the interaction between TRX and TXNIP, compared to control group treated with no candidates. Further, when TXNIP protein is over-expressed, insulin sensitivity is reduced and blood glucose level is increased. Therefore, the candidates can be determined as diabetes therapeutic agents that function to lower blood glucose levels in diabetes by examining whether the candidates diminish the interaction between TRX and TXNIP, compared to control group treated with no candidates.
In still another embodiment, the present invention provides a method for screening an inhibitor of TRX activity using the tertiary structure of the modified TXNIP protein or the modified TRX-TXNIP complex.
The method for screening an inhibitor of TRX activity may preferably include (a) producing or selecting a candidate peptide of inhibiting TRX activity or a TRX-binding compound using the tertiary structure of N-TXNIP (the N-terminal domain of thioredoxin-interacting protein) having the atomic coordinates shown in Table 9; the tertiary structure of the modified TRX(thioredoxin)-TXNIP(thioredoxin-interacting protein) complex having the atomic coordinates shown in Table 10; or the tertiary structure of the modified TRX-TXNIP complex having the atomic coordinates shown in Table 11; and (b) examining whether the candidate peptide or compound produced or selected in Step (a) inhibits TRX activity; but is not limited thereto.
In particular, the method for screening an inhibitor of TRX activity may be used to produce a candidate peptide or compound inhibiting TRX activity, on the basis of one or more amino acid sequences selected from the group consisting of the amino acid sequences of β18 and β15 strands of T-TXNIP which are located in the center of the interaction interface between TRX and TXNIP, and combinations thereof, using the tertiary structure of N-TXNIP (the N-terminal domain of thioredoxin-interacting protein) having the atomic coordinates shown in Table 9; the tertiary structure of the modified TRX(thioredoxin)-TXNIP(thioredoxin-interacting protein) complex having the atomic coordinates shown in Table 10; or the tertiary structure of the modified TRX-TXNIP complex having the atomic coordinates shown in Table 11, but is not limited thereto.
In the present invention, the tertiary structures of N-TXNIP(K5A/K6A) (SEQ ID NO: 8); and the modified TRX-TXNIP complex were investigated. It was confirmed that β18 and β15 strands of T-TXNIP are located in the center of the interaction interface between TRX and TXNIP. Therefore, a peptide of inhibiting TRX activity can be synthesized or designed using the amino acid sequences of T-TXNIP β18 and β15 strands involved in the interaction with TRX or/and combinations thereof. In addition, a compound that binds to TRX and regulates its activity can be designed or/and synthesized using information about of β18 and β15 strands in the interaction interface between TRX and TXNIP. Preferably, the compound may be a small compound, but is not limited thereto. It is also known that binding of the TXNIP protein to TRX inhibits TRX activity. Therefore, when a peptide or a compound binding to TRX is synthesized using the information about the interaction interface between TRX and TXNIP, it can be a substance that binds to TRX and regulates its activity, like the TXNIP, but is not limited thereto.
The inhibition of TRX activity may include inhibition of Redox-potential of TRX or inhibition of interaction with a protein that is known to interact with TRX, but is not limited thereto.
By the method for screening an inhibitor of TRX activity, it is possible to further screen a substance having a TRX-inhibitory activity stronger than the TRX inhibitor screened in Step (b) using the designed tertiary structures. In such a manner, it is possible to investigate a substance having a higher TRX-inhibitory activity.
A step of determining the screened peptide or compound as an anticancer agent when the TRX-binding ability of the peptide or compound is higher than that of TXNIP may be further included.
In still another aspect, the present invention provides a method for screening a substance regulating TXNIP function using the tertiary structure of the modified TXNIP protein or modified TRX-TXNIP complex.
The method for screening a substance regulating TXNIP function may preferably include: (a) producing or selecting a candidate regulating TXNIP function using a tertiary structure of N-TXNIP (the N-terminal domain of thioredoxin-interacting protein) having the atomic coordinates shown in Table 9; a tertiary structure of the modified TRX(thioredoxin)-TXNIP(thioredoxin-interacting protein) complex having the atomic coordinates shown in Table 10; or a tertiary structure of the modified TRX-TXNIP complex having the atomic coordinates shown in Table 11; and (b) examining whether the candidate produced or selected in Step (a) regulates TXNIP function; but is not limited thereto. Further, the method may further include the step of determining the candidate regulating TXNIP function as a therapeutic agent for diabetes when the candidate reduces or inhibits TXNIP activity, compared to control group treated with no candidates.
Hereinafter, the present invention will be described in more detail with reference to the following Examples. However, these Examples are for illustrative purposes only, and the invention is not intended to be limited by these Examples.
Since TXNIP could not be expressed as a soluble protein without TRX, plasmids co-expressing human TRX and TXNIP were constructed using a two-promoter vector system. Further, T-TXNIP (residues 3-317) with an N-terminal hexahistidine-tag containing an integrated rTEV protease cleavage site was cloned into pProEX HTa plasmid (Invitrogen), which expresses tag-free human TRX under the control of the T7 promoter. A plasmid co-expressing TRX(C35A)(SEQ ID NO:3) which was prepared by substituting alanine for cysteine at position 35 of human TRX and N-TXNIP was constructed by cloning N-TXNIP(residues 3-156) with an N-terminal hexahistidine-tag containing the integrated rTEV protein cleavage site into pPROEX-HTa plasmid (Invitrogen) which expresses tag-free human TRX(C35A)(SEQ ID NO:3) under the control of the T7 promoter using the two-promoter vector system. N-TXNIP was subcloned into the pHis-Parallel1 expression vector, which is a protein expression vector encoding an N-terminal hexahistidine tag with an rTEV protease cleavage site. For NMR experiments, TRX was subcloned into pET21 vector, which contains a C-terminal hexahistidine-tag. Cloning of T-TXNIP and TRX is described in more detail below.
To synthesize and amplify T-TXNIP gene (T-TXNIP(3-317)) starting from amino acid 3 as the N-terminus and ending at amino acid 317 by PCR, two oligonucleotides were designed as follows and synthesized using a DNA synthesizer (Table 1).
ACA TCT CAG AGC TGG
The forward primer contains a base sequence corresponding to the NcoI restriction enzyme recognition site, which is underlined. The reverse primer has a stop codon, which is indicated in italics and the restriction enzyme NotI recognition site underlined.
Human-derived TXNIP gene was used as a template to carry out PCR by the following procedure: 1 μl of TXNIP DNA, 1 μl of 10 mM dNTP (final concentration: 0.2 mM), 1 μl each of forward and reverse primers (final concentration: 0.2 μM), 0.5 μl of Taq DNA polymerase (5 U/μl, NEB, USA), and 5 μl of PCR buffer (NEB) are added to 40.5 μl of distilled water to prepare a reaction solution. After reaction was allowed at 95° C. for 3 minutes, 30 cycles of 95° C. for 30 seconds; 55° C. for 45 seconds; 72° C. for 1 minute and 30 seconds were performed. The reaction solution was separated on a 1% agarose gel by electrophoresis, and a desired DNA fragment was extracted and dissolved in 40 μl of distilled water (hereinafter, referred to as T-Txnip N/N).
Plasmid pPROEX was completely cleaved with restriction enzymes, NcoI and NotI, and separated on a 1% agarose gel. 0.5 μg of T-TXNIP N/N and 0.6 μg of the plasmid vector pPROEX N/N were put in a reaction tube, and then 1 μl of 10× ligation solution (500 mM tris-HCl, pH 7.8, 100 mM magnesium chloride, 100 mM DTT, 10 mM ATP) and 10 U of T4 DNA ligase were added thereto and distilled water was added to a final volume of 10 μl, and allowed to react at 4° C. for 12 hours. This reaction solution was added to E. coli DH5α cell for transformation, and plated on a 100)(g/ml LB-ampicillin medium to select E. coli transformants. Plasmids were extracted therefrom, and acquisition of pPROEX-T-TXNIP was confirmed by using restriction enzyme and sequencing. The nucleotide sequences of the N-TXNIP and T-TXNIP genes cloned into the recombinant plasmids were analyzed in accordance with the method of Sanger et al. (Sanger, F. et al., 1977 PNAS USA 74:5463) using a Big-Dye Cycle Sequencing System (Applied Biosystems, U.S.A) and a ABI 377 DNA sequencer.
To synthesize and amplify TRX gene by PCR, two oligonucleotides were designed as follows and synthesized using a DNA synthesizer (Table 2).
The forward primer contains a base sequence corresponding to the NdeI restriction enzyme recognition site (underlined), and the reverse primer contains a stop codon (in italics) and a base sequence corresponding to the restriction enzyme XhoI recognition site (underlined).
Human-derived TRX gene was used as a template to carry out PCR by the following procedure: 40.5 μl of distilled water was added to 1 μl of Trx DNA, 1 μl of 10 mM dNTP (final concentration: 0.2 mM), 1 μl each of forward and reverse primers (final concentration: 0.2 μM), 0.5 μl of Taq DNA polymerase (5 U/μl, NEB, USA), 5 μl of PCR buffer (NEB) to prepare a reaction solution. After reaction was allowed at 95° C. for 3 minutes, 30 cycles of 95° C. for 30 seconds; 55° C. for 45 seconds; 72° C. for 30 seconds were performed. The reaction solution was separated on a 1% agarose gel by electrophoresis, and a desired DNA fragment was extracted and dissolved in 40 μl of distilled water (hereinafter, referred to as Trx N/X).
Since TXNIP could not be expressed as a soluble protein without TRX protein, plasmids co-expressing human TRX and T-TXNIP were constructed using a two-promoter vector system as follows:
Recombinant plasmid pPROEX-T-TXNIP was completely cleaved with restriction enzymes, NdeI and XhoI, and separated on a 1% agarose gel. 0.3 μg of Trx N/X and 0.2 μg of the plasmid vector pPROEX-T-XNIP N/X were put in a reaction tube, and then 1 μl of 10× ligation solution (500 mM tris-HCl, pH 7.8, 100 mM magnesium chloride, 100 mM DTT, 10 mM ATP) and 10 U of T4 DNA ligase were added thereto and distilled water was added to a final volume of 10 μl, and allowed to react at 4° C. for 12 hours. This reaction solution was added to E. coli DH5α cells for transformation, and plated on a 100 μg/ml LB-ampicillin medium to select E. coli transformants. Plasmids were extracted therefrom, and acquisition of pPROEX-T-TXNIP-TRX was confirmed by using restriction enzyme and sequencing. The nucleotide sequence of the TXNIP gene cloned into the recombinant plasmid was analyzed in accordance with the method of Sanger et al. (Sanger, F. et al., 1977 PNAS USA 74:5463) using a Big-Dye Cycle Sequencing System (Applied Biosystems, USA) and a ABI 377 DNA sequencer.
The series of the procedures is shown in the diagram of
To substitute alanine for cysteine at position 35 of TRX gene, two oligonucleotides were designed as follows and synthesized using a DNA synthesizer (Table 3).
CCA AAA TGA TCA AGC CTT TC
AGG CCC ACA CCA CGT GGC TG
The forward and reverse primers contain sequences (underlined) encoding the amino acids substituted with alanine (Ala) for cysteine (Cys). The expression vector pPROEX-T-TXNIP-TRX prepared in Example 1-4 was used as a template to carry out site-directed mutagenesis by the following procedure: 40.5 μl of distilled water was added to 0.5 μl of pPROEX-T-TXNIP-TRX, 1 μl of 100 mM dNTP, 1 μl each of forward and reverse primers (final concentration: 0.2 μM), 1 μl of pfu DNA polymerase (2.5 U/μl, Stratagene, USA), 5 μl of mutagenesis buffer (Stratagene, USA) to prepare a reaction solution. After reaction was allowed at 95° C. for 30 seconds, 18 cycles of 95° C. for 30 seconds; 55° C. for 60 seconds; 68° C. for 8 minutes were performed. After completion of the reaction, 1 μl of DpnI (NEB, USA) was added to the reaction solution, and allowed to react at 37° C. for 1 hour to remove pPROEX-T-TXNIP-TRX used as the template. This reaction solution was added to E. coli DH5α cell for transformation, and plated on a 100 μg/ml LB-ampicillin medium to select E. coli transformants. Plasmids were extracted therefrom, and the nucleotide sequence of TRX gene undergoing mutagenesis was examined.
To substitute serine for cysteine at position 120 of TXNIP gene, two oligonucleotides were designed as follows and synthesized using a DNA synthesizer (Table 4).
The forward and reverse primers contain sequences (underlined) encoding the amino acids substituted with serine for cysteine. In addition, for substitution of serine for cysteine at position 170 of TXNIP gene, the primers of SEQ ID NOs. 19 and 20 of the following Table 5 were synthesized. For substitution of serine for cysteine at position 205 of TXNIP gene, the primers of SEQ ID NOs. 21 and 22 of the following Table 6 were synthesized. For substitution of serine for cysteine at position 267 of TXNIP gene, the primers of SEQ ID NOs. 23 and 24 of the following Table 7 were synthesized.
The expression vector pPROEX-T-TXNIP-TRX(C35A) prepared by TRX mutagenesis was used as a template to carry out site-directed mutagenesis by the following procedure: 40.5 μl of distilled water was added to 0.5 μl of pPROEX-T-TXNIP-TRX(C35A), 1 μl of 100 mM dNTP, 1 μl each of forward and reverse primers of Table 4 (final concentration: 0.2 μM), 1 μl of pfu DNA polymerase (2.5 U/μl, Stratagene, USA), 5 μl of mutagenesis buffer (Stratagene, USA) to prepare a reaction solution. After reaction was allowed at 95° C. for 30 seconds, 18 cycles of 95° C. for 30 seconds; 55° C. for 60 seconds; and 68° C. for 8 minutes were performed. After completion of the reaction, 1 μl of DpnI (NEB, USA) was added to the reaction solution, and allowed to react at 37° C. for 1 hour to remove pPROEX-T-TXNIP-TRX(C35A) used as the template. This reaction solution was added to E. coli DH5α cell for transformation, and plated on a 100 μg/ml LB-ampicillin medium to select E. coli transformants. Plasmids were extracted therefrom, and the nucleotide sequence of Txnip gene undergoing mutagenesis was examined. To obtain pPROEX-T-TXNIP(C120,170S)-TRX(C35A), pPROEX-T-TXNIP(C120S)-TRX(C35A) as a template and the primers of Table 5 were used. pPROEX-T-TXNIP(C120,170S)-TRX(C35A) as a template and the primers of Table 6 were used to obtain pPROEX-T-TXNIP(C120,170,205S)-TRX(C35A). pPROEX-T_TXNIPC120,170,205S-TRXC35A as a template and the primers of Table 7 were used to obtain pPROEX-T-TXNIP(C120,170,205,267S)-TRX(C35A). The nucleotide sequences thereof were examined in the same manner as in Example 1-4.
A series of the mutagenesis procedures is shown in the diagram of
Expression of TRX and T-TXNIP complex, their modified complexes, and TRX(C35A)-N-TXNIP complex was induced with 0.5 mM IPTG in E. coli Rosetta-Gami™ (DE3) cells at 21° C. for 40 hours. Expression of the N-TXNIP(K5A/K6A) mutant was induced with 0.5 mM IPTG in E. coli C41(DE3) cells at 21° C. for 16 hours. Recombinant proteins were purified by Ni-NTA affinity chromatography, treated with rTEV protease to remove hexahistidine-tags and further purified by size-exclusion chromatography and additional Ni-NTA affinity chromatography. The purified proteins were dialyzed against 50 mM Tris-HCl (pH 7.0). A selenomethionine (SeMet)-substituted complex of TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6), and SeMet-substituted N-TXNIP(K5A/K6A) were expressed in the methionine auxotroph E. coli B834(DE3) (Novagen) grown in minimal medium supplemented with 50 mg/ml SeMet under the same conditions as the cells containing the native plasmid. The SeMet-substituted proteins were purified as for the native proteins. TRX and its modified protein were expressed in E. coli C41 (DE3) using 0.5 mM IPTG at 21° C. for 18 hours and purified by Ni-NTA agarose affinity and size-exclusion chromatography. The proteins were then dialyzed against 50 mM potassium phosphate (pH 6.6) for NMR experiments. E. coli C41 (DE3) transformed with plasmids encoding N-TXNIP or its modified protein were grown in M9 minimal medium enriched with (15NH4)2SO4 (99% 15N; Cambridge Isotope Laboratory, Inc.) as the sole nitrogen source. All 15N-labeled proteins were purified using Ni-NTA affinity chromatography. The proteins were then treated with rTEV protease to remove the hexahistidine-tags and dialyzed against 50 mM potassium phosphate (pH 6.6) as a final step before NMR.
The expression vector pPROEX-T-TXNIP(C120,170,205S,C267S)-TRX(C35A) prepared in Example 2-1 was transformed into a host cell, E. coli Rosetta-Gami(DE3) (Novagen Inc.). The transformed E. coli strain was cultured with shaking in 100 μg/ml LB-ampicillin-containing LB medium (1% bactotrypton, 0.5% yeast extract, 1% sodium chloride) for 12 hours, and then 2 ml thereof was transferred to 50 ml of LB medium (containing 100 ug/ml ampicillin). When absorbance at 600 nm was about 0.4-0.6, the culture temperature was reduced from 37° C. to 21° C., and the IPTG was added to a final concentration of 0.5 mM, followed by culture for about 40 hours. 10 ml of E. coli was taken and centrifuged at 6,500 rpm for 10 minutes to obtain a cell pellet, which was suspended in a buffer solution containing 50 mM Tris pH 8.0, 500 mM sodium chloride, 10% glycerol, and 1 mM DTT. Cells were disrupted using an ultrasonicator (VCX 500, Sonics, USA) on ice. This solution was centrifuged using a centrifuge at 16,000 rpm for 30 minutes, and then the supernatant and pellet were subjected to 15% SDS-polyacrylamide gel electrophoresis in accordance with the method of Laemmli et al., (1970 Nature 227: 680), and then proteins were stained with Coomassie Brilliant Blue for analysis.
E. coli in which T-TXNIP(C120,170,205,267S) and TRX(C35A) were expressed by the method in Example 2-1, was cultured in a 2-liter volume, and then centrifuged at 6,000 rpm for 10 minutes using a centrifuge to obtain an E. coli cell pellet, which was suspended in a buffer solution containing 50 mM Tris pH 8.0, 500 mM sodium chloride, 10% glycerol, and 1 mM DTT. Cells were disrupted using an ultrasonicator (VCX 500, Sonics, USA) on ice. This solution was centrifuged using a centrifuge at 16,000 rpm for 60 minutes, and then the supernatant was used in the following procedure:
The supernatant thus obtained was bound to Ni-NTA resin (Quiagen, USA) previously equilibrated with the buffer solution, and then Ni-NTA column was washed with a buffer solution containing 50 mM Tris pH 8.0, 500 mM sodium chloride, 10% glycerol, 1 mM DTT, and 30 mM Imidazole. Elution was carried out using a buffer solution containing 50 mM Tris pH 8.0, 500 mM sodium chloride, 10% glycerol, 1 mM DTT, and 250 mM Imidazole, and then SDS-PAGE was performed to collect only T-TXNIP(C120,170,205,267S)(SEQ ID NO: 6) and TRX(C35A)(SEQ ID NO:3) proteins, which were used in the following procedure: The T-TXNIP(C120,170,205,267S)(SEQ ID NO: 6) and TRX(C35A)(SEQ ID NO:3) proteins obtained in the above procedure were concentrated to 1 ml, and applied to a size-exclusion chromatography column (Superdex™ 200, 10/30 GL, GE) equilibrated with a buffer solution containing 50 mM Tris pH 8.0, 500 mM sodium chloride, 10% glycerol, and 2 mM DTT. Proteins were separated according to their molecular weight, and analyzed by electrophoresis, thereby collecting only T-TXNIP(C120,170,205,267S)(SEQ ID NO: 6) and TRX(C35A)(SEQ ID NO:3) proteins.
A Superdex™ 200 10/300 GL gel filtration column (GE Healthcare) installed on an Acta purifier FPLC system (GE Healthcare) was equilibrated with 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 10% glycerol at a flow rate of 0.4 ml/min at room temperature. Purified TRX-T-TXNIP and its mutants were injected onto the column Ovalbumin was used as a molecular weight standard.
To test the in vivo interprotomer interaction between TXNIP molecules, HEK 293T cells were transfected with plasmids expressing HA-tagged-TXNIP and FLAG-tagged T-TXNIP. 24 hours later, the cells were harvested and lysed in the 50 mM iodoacetamide-containing buffer [0.5% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM NaF, 1 mM AEBSF, 2 μg/mL leupeptin, 5 μg/mL aprotinin and 20 mM HEPES (pH 7.2)]. After centrifugation at 16,000 rpm for 20 minutes, the supernatant was incubated with anti-FLAG M2 agarose (Sigma) at 4° C. for 12 hours. The immobilized proteins were collected by centrifugation and washed three times with the lysis buffer. The bound proteins were subjected to SDS-PAGE under reduced and non-reduced conditions. For the assay demonstrating the TXNIP-TXNIP interaction, HEK 293T cells were transfected with combinations of expression plasmids. 24 hours later, the cells were harvested and lysed in the lysis buffer. After centrifugation at 16,000 g for 20 minutes, the supernatants were incubated at 4° C. for 12 hours with monoclonal anti-FLAG M2 agarose beads (Sigma) for immunoprecipitation, or with glutathione-conjugated sepharose beads (GE Healthcare) for pull-down assay. The immobilized proteins were collected by centrifugation and washed three times with lysis buffer. Bound proteins or WCLs were eluted by boiling in SDS sample buffer. To detect HA-tagged proteins, FLAG-tagged proteins or GST-fused proteins, the rabbit polyclonal anti-HA antibody (Santa Cruz Biotechnology), rabbit polyclonal anti-FLAG antibody (Santa Cruz Biotechnology) or rabbit polyclonal anti-GST antibody (Santa Cruz Biotechnology) was used and then HRP (horseradish peroxidase)-conjugated secondary antibody (Santa Cruz Biotechnology) was used to visualize the specific target bands in the membrane.
For immunoprecipitation assay showing the effect of TRX on the TXNIP-TXNIP interaction, the transfected HEK 293T cells were harvested and lysed in lysis buffer containing 0.5% Triton X-100, 150 mM NaCl, 10% glycerol and 20 mM HEPES (pH 7.2) supplemented with complete protease inhibitor cocktail (Roche). After incubation at 4° C. for 30 minutes, lysate was centrifuged at 16,000 g for 20 minutes. The supernatants were then precleared by incubation at 4° C. for 2 hours with 20 μl of protein G-sepharose beads (GE Healthcare) and centrifuged at 10,000 g for 5 minutes. The precleared lysate was incubated at 4° C. for 14 hours with the rabbit polyclonal anti-HA antibody (Santa Cruz Biotechnology), followed by further incubation at 4° C. for 5 hours with protein G-sepharose beads. After immunoprecipitation, the beads were washed five times with lysis buffer. Bound proteins or WCLs were eluted by boiling in LDS-PAGE loading buffer. To detect HA-tagged proteins or FLAG-tagged proteins, the mouse monoclonal anti-HA antibody (Abcam) or the mouse anti-FLAG antibody (Sigma) was used and then HRP (horseradish peroxidase)-conjugated secondary antibody (Santa Cruz Biotechnology) or peroxidase-conjugated light chain specific secondary antibody (Jackson ImmunoResearch Laboratories. Inc) was used to visualize the specific target bands in the membrane.
Because N-TXNIP was not crystallized, N-TXNIP(K5A/K6A)(SEQ ID NO: 8) with reduced surface entropy was crystallized using the sitting drop vapor-diffusion method at 21° C. The best crystals were obtained with sodium-potassium phosphate (0.75 M) and 0.1 M HEPES-Na (pH 7.5). Diffraction data were collected at beamline 4A of Pohang Accelerator Laboratory (PAL) at a resolution of 1.6 Å. SeMet-substituted K5A/K6A crystals were grown under the same crystallization conditions as for the wild-type protein (native protein).
Multiple-wavelength anomalous diffraction (MAD) data for the SeMet-substituted crystals were collected at beamline 6 C of PAL at a resolution of 1.8 Å. The TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NOL 6) complex crystals were optimized in 0.16 M sodium citrate and 16% PEG 3350, and diffraction data were collected at a resolution of 2.0 Å at PAL beamline 4A. SeMet-substituted crystals were grown under 0.2 M sodium citrate and 20% PEG 3,350. MAD data were collected at a resolution of 3.0 Å at PAL beamline 6 C. Crystals of the TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) complex were optimized using conditions similar to those for the other complex, and diffraction data were collected at a resolution of 2.7 Å at PAL beamline 4A. All data were processed with the HKL2000 package. The N-TXNIP(K5A/K6A) (SEQ ID NO: 8) structure was determined by analyzing anomalous signals from Se atoms with the program SOLVE55. Density modification and subsequent automated model building were carried out using RESOLVE. The N-TXNIP(K5A/K6A) (SEQ ID NO: 8) crystal structure was solved at a resolution of 1.6 Å using the molecular replacement method (MR) with the program MOLREP, based on the partially refined structure of the SeMet crystal. The SeMet-substituted TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) structure was determined using SOLVE, and subsequent automated model building was carried out using RESOLVE. The complex structure at a resolution of 2.0 Å was solved by MR using the partially refined SeMet complex structure. The TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) complex structure was determined by MR using the TRX(C35A)(SEQ ID NO:3) and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complex model. All structures were revised using COOT and refined with REFMAC5.
All crystallographic data investigated by the method are summarized in the following Table 8. Further, the atomic coordinates of N-TXNIP(K5A/K6A) (SEQ ID NO: 8), COM1, and COM2 are summarized in the following Tables 9, 10, and 11, respectively.
NMR interaction experiments were carried out by recording 1H-15N NMR HSQC spectra of 15N-labeled N-TXNIP upon addition of unlabeled TRX or its mutant, which was reduced with 5 mM DTT and dialyzed against 50 mM potassium phosphate (pH 6.6) prior to the interaction study to remove excess DTT.
The 1H-15N HSQC spectra of all proteins were measured on a Bruker 900 MHz NMR spectrometer at the Korea Basic Science Institute (Ochang, Korea). The NMR measurements were performed using 0.3 mM 15N-labeled protein in 50 mM potassium phosphate (pH 6.6) containing 10% D2O at 25° C. All NMR spectra were processed with Topspin 2.1 and analyzed with the program SPARKY 3.1.
TRX activity was assayed using the insulin disulfide reduction assay. The transiently transfected HEK 293T cells were lysed in lysis buffer containing 20 mM HEPES (pH 7.9), 100 mM KCl, 300 mM NaCl, 10 mM EDTA, 0.1% Nonidet P-40, and protease inhibitors. To reduce TRX, cell extracts (20 μg) were incubated at 37° C. for 20 minutes with 2 μl of DTT activation buffer containing 50 mM HEPES(pH 7.6), 1 mM EDTA, 1 mg/ml BSA, and 2 mM DTT in a total volume of 70 μl. 40 μl of reaction mixture taken from a solution containing 200 μl of 1 M HEPES (pH 7.6), 40 μl of 0.2 M EDTA, 40 μl of NADPH (40 mg/ml), and 500 μl of insulin (10 mg/ml) was then added. Rat thioredoxin reductase (100 U/ml) was added to reaction and incubated at 37° C. for 20 minutes. The reaction was stopped with 6 M guanidine-HCl and 1 mM DNTB (3-carboxy-4-nitrophenyl disulfide), and absorbance was measured at 412 nm.
The TRX and T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complex was used to circumvent non-functional cysteine-induced aggregation. The complex (at a concentration of 0.05 mM) was incubated with H2O2 at concentrations in the range of 0 to 10 mM in 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, and 10% glycerol at 37° C. The TRX(C37A) and T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) complex was also used to avoid TRX dimerization and non-functional cysteine-induced aggregation. This complex was incubated with 0 to 3 mM diamide in 50 mM Tris-HCl(pH 8.0), 500 mM NaCl, and 10% glycerol at 37° C. After a 30-minute reaction, the samples were injected onto a HiLoad™ 16/60 Superdex™ 75 gel filtration column (GE Healthcare) installed on an AKTA purifier FPLC system at a flow rate of 1 ml/min at room temperature. To examine the role of TRX Cys35 for dissociation between TRX and TXNIP, the TRX(C35A)(SEQ ID NO:3)-T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complex was incubated at room temperature for 1 hour with 3.3 mM diamide and then injected onto the Superdex™ 75 10/300 GL gel filtration column. All fractions were subjected to SDS-PAGE.
For the analysis of interprotomer disulfide bond between TXNIP molecules by mass spectrometry in vivo, HEK 293T cell were transfected with expression plasmid expressing TXNIP fused with GST. 24 hours later, the transfected cells were harvested and lysed in lysis buffer containing 0.5% Triton X-100, 150 mM NaCl, 10% glycerol and 20 mM HEPES (pH 7.2) supplemented with complete protease inhibitor cocktail (Roche). After incubation at 4° C. for 30 minutes, lysates were centrifuged at 16,000 g for 20 minutes. The supernatants were overnight-incubated at 4° C. with Glutathione Sepharose 4FF (GE Healthcare) and centrifuged at 10,000 g for 5 minutes. Next, the supernatant was discarded and the resin was washed five times with lysis buffer. Bound proteins to resin were eluted by boiling in an LDS-PAGE loading buffer (life technologies).
For analysis by mass spectrometry in vitro, purified TRX(C73A)-T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) complex was incubated with 100 mM DTT for 1 hour at room temperature and injected to the Superdex™ 200 10/300 GL gel filtration column installed on an AKTA purifier FPLC system to obtain T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) from remained protein complex and TRX(C73A). The fractions containing T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) were dialyzed against 50 mM Tris-HCl (pH 8.0), 500 mM NaCl and 10% glycerol to induce the formation of disulfide bonds between TXNIP molecules through air oxidation. Dialyzed proteins were then subjected to SDS-PAGE under non-reducing conditions.
The high molecular TXNIP complex-containing gel pieces were destained in the 25 mM ammonium bicarbonate and 50% acetonitrile solution, dehydrated with 100% acetonitrile and dried at room temperature. Alkylation of free cysteines was performed by addition of 55 mM iodoacetamide in 25 mM ammonium bicarbonate, followed by incubation at 25° C. for 1 hour in the dark. The gel was washed with 25 mM ammonium bicarbonate and 50% acetonitrile solution, dehydrated with 100% acetonitrile and dried at room temperature. The gel pieces were rehydrated with a solution of sequencing-grade trypsin (12.5 ng/μL; Promega, Madison, Wis., U.S.A.) in 25 mM ammonium bicarbonate and incubated at 37° C. for 16 hours for protein digestion. Next, supernatants were transferred to fresh tubes, and the remaining peptides were sequentially extracted by incubating gel pieces with 50% acetonitrile in 25 mM ammonium bicarbonate, 50% acetonitrile in 0.5% trifluoroacetic acid (TFA), and 70% acetonitrile in 0.5% TFA. The extracted peptides were combined and dried in a vacuum evaporator (MIVAC DUO, Genevac, Ipswich, England). The peptides were stored at −20° C. until use.
The peptides obtained in 10-2 were diluted with 0.4% acetic acid to achieve concentrations of 1 μg/μL and an aliquot (˜1 μg) was injected to a reversed-phase Magic C18aq column (15 cm×75 μm) on an Eksigent nanoLC-ultra 1D plus system at a flow rate of 300 nL/min. The column was equilibrated with 95% buffer A (0.1% formic acid in H2O)+5% buffer B (0.1% formic acid in acetonitrile) prior to use. Peptides were eluted with a linear gradient from 10% buffer B to 40% buffer B over 40 minutes. The HPLC system was coupled to a Q Exactive quadrupole mass spectrometer (Thermo Scientific, San Jose, Calif., USA). The Q Exactive instrument was operated in data dependent mode. Survey full-scan MS spectra (m/z 300-2,000) were acquired in the Orbitrap with a resolution of 75,000, MS/MS spectra of the twelve most intense ions from the MS1 scan with charge state ≧2 were acquired with the following settings: resolution, 17,500; isolation width, 2 m/z; normalized collision energy, 27%; dynamic exclusion duration, 30s. ion selection threshold, 4.00E+03 counts.
The acquired MS/MS spectra were searched using X!Tandem (open source software, available fromproteome.ca/opensource.html) against the SwissProt database. Briefly, peptide mass tolerance was set to ±15 ppm, cleavage specificity was set to trypsin, allowing for a maximum of one missed cleavages. A variable modification of methionine oxidation (+15.9949 Da) and carbamidomethylated cysteine (+57.0215 Da) was allowed. Peptide assignment was performed with the Trans Proteomics Pipeline provided by Institute for Systems Biology (TPP, version 4.5 RAPTURE rev 2, roteomecenter.org). From the X!Tandem search output, peptides with probabilities greater than 0.9 were included in the subsequent Protein-Prophet, and proteins having protein probability of more than 0.9 were gathered. From the results, the contaminants (e.g. Keratin and trypsin artificial) were removed. Analysis for identification of disulfide linkages was performed using DBond software (version 3.02, prix.hanyang.ac.kr/download/dbond.j sp) (PMID: 19902913).
Repeated experiments aimed at the overexpression of the recombinant full-length TXNIP protein as a soluble protein have been tried. However, when only TXNIP was expressed, it behaved as a molten globular protein showing a low binding activity. Under these circumstances, it was tried to express TXNIP as a soluble protein by carrying out constructional changes in TXNIP protein and co-expressing TRX and TXNIP.
In particular, because TRX (containing five cysteines) and TXNIP (containing 11 cysteines) are redox proteins whose properties make them difficult to handle in vitro, the present inventors engineered a cysteine(Cys35) to alanine (Ala) mutation in TRX to prevent further reactions after interaction between the two proteins, as well as combinatorial cysteine mutations in the tandem arrestin-like domain of TXNIP (T-TXNIP, amino acid 3 to 317) to prevent non-specific aggregation and to generate crystals suitable for X-ray diffraction. Two mutant complexes, TRX(C35A)-T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complex (COM1) and TRX(C35A)(SEQ ID NO:3)-T-TXNIP(C170S/C205S/C267S)(SEQ ID NO: 5) complex (COM2), were crystallized for X-ray diffraction and their structures were determined using the multiple anomalous wavelength dispersion method, together with the molecular replacement method. The structures of COM1 and COM2, which were refined to resolutions of 2.0 Å and 2.7 Å, respectively, are shown in
Further, T-TXNIP was comparable to the native TXNIP and its mutant in their ability to bind TRX and inhibit TRX activity (
The structures of COM1 and COM2 are essentially identical, each contains two heterodimeric complexes of TRX and T-TXNIP in an asymmetric unit, with a large interface between the two T-TXNIP molecules (
Since the structures of COM1 and COM2 are essentially identical and the TRX and T-TXNIP complex exists as a single heterodimeric species in solution, the T-TXNIP (chain C) and TRX (chain D) complex (
As shown in
Cys247 in TXNIP is the most important residue for the interaction with TRX Cys32. Examination of the intermolecular disulfide bond between TRX Cys32 and T-TXNIP Cys247 provides insight into how TXNIP negatively regulates TRX (
The interaction between TXNIP and TRX requires oxidized TXNIP, which was thought to contain an intramolecular disulfide bond between Cys63 and Cys247, and reduced TRX32. According to the T-TXNIP structure shown in
First, the in vivo interprotomer interaction between TXNIP molecules was examined using 293T cells transfected with HA-tagged TXNIP and FLAG-tagged T-TXNIP-expressing plasmids. At this time, cysteine-blocking reagent iodoacetamide-containing lysis buffer was used to avoid non-specific extra redox reaction during cell lysis. The results are shown in
As shown in
Further, coimmunoprecipitation assays were performed using lysates of 293T cells transfected with FLAG-tagged TXNIP and HA-tagged TXNIP-expressing plasmids, and the results are shown in
As shown in
Further, the roles of Cys63 in the N-terminal domain and Cys247 in the C-terminal domain in the formation of interprotomer disulfide bonds were evaluated using GST-fused- and FLAG-tagged-TXNIP. The substitution of Cys247 with serine in both the GST-fused- and the FLAG-tagged-TXNIP molecules abolished the formation of interprotomer disulfide bonds, unlike the substitution of Cys247 with serine in the GST-fused TXNIP (
In addition, mass spectrometry was employed to analyze the interprotomer disulfide bond between Cys63 and Cys247. To achieve this, the non-specific covalent oligomerization-preventing T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) protein was isolated from the TRX(C73A)-T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) complex (
As shown in Table 12, above, the sites of disulfide bonds were identified at residues Cys63-Cys190, Cys63-Cys247, Cys63-Cys63, Cys190-Cys247, and Cys247-Cys247 with Dbond score >20. However, the distribution of the disulfide bond site was significantly different between the bands. In ˜60 kDa band, Cys63-Cys247 was identified with 5 spectra comprising the major disulfide bond while Cys63-Cys190 in ˜32 kDa band appeared as the majority with 93 spectra out of 102. Furthermore, the sites of free cysteines which appeared as carbamidomethyl cysteines after alkylation were identified to have different distributions.
This demonstrates that the majority of Cys63 are disulfide-bonded with Cys190 in ˜32 kDa band (a monomeric T-TXNIP) and with Cys247 in ˜60 kDa band (an interprotomer-interacting T-TXNIP molecules), and a great amount of Cys190 remains as free cysteines at the ˜32 kDa band.
A representative MS/MS spectrum for Cys63-Cys190 identified from ˜32 kDa band and that for Cys63-Cys247 identified from ˜60 kDa band are shown in
Therefore, these data collectively demonstrate that a head-to-tail interprotomer disulfide bond between Cys63 and Cys247 is present in TXNIP molecules.
As shown in
These results suggest that the stable formation of TRX and T-TXNIP heterodimeric complexes appears to involve the transient interaction of TRX with the interprotomer disulfide bond between TXNIP molecules.
As shown in
The addition of TRX caused substantial chemical shifts, pointing to a direct interaction between N-TXNIP and TRX (
Further, TRX muteins were added and 1H-15N HSQC spectra of 15N-labeled N-TXNIP were monitored to examine interaction between N-TXNIP and TRX. There were no significant chemical shift changes when C32A or C35A TRX mutants were added to 15N-labeled N-TXNIP (
Because reduced TRX only binds to oxidized T-TXNIP having a disulfide bond, it was assumed that a disulfide bond might also be involved in the interaction between N-TXNIP and TRX. To test this assumption, the structure of N-TXNIP at 1.6 Å resolution was determined and shown in
As a result, the structure of N-TXNIP is very similar to that of the corresponding domain in T-TXNIP. However, unlike the case of T-TXNIP, there is an unexpected intramolecular disulfide bond between Cys63 and Cys120 (
In addition, there is a significant change in the β8 to β10 region (
The transient interaction of TRX with the interprotomer disulfide bond between Cys63 and Cys247 in TXNIP must result in the stable intermolecular interaction between TRX Cys32 and TXNIP Cys247, as seen in the complex structure of
The above experiments suggest that interaction between TRX and TXNIP is related to a novel mechanism of disulfide bond switching: the replacement of a head-to-tail interprotomer TXNIP Cys63-TXNIP Cys247 disulfide bond with an interdomain TXNIP Cys63-Cys190 disulfide bond and a de novo intermolecular TXNIP Cys247-TRX Cys32 disulfide bond.
The regulation of TRX by TXNIP is known to be redox-dependent. ROS are involved in activation of the oxidative stress-responsive pathway and can alter protein structure and/or function. To assess the effect of ROS on interaction between TRX and TXNIP, the TRX-T-TXNIP complexes were treated with ROS. To prevent non-functional cysteine-induced non-specific aggregation of T-TXNIP and dimerization of TRX, T-TXNIP(C120S/C170S/C205S/C267S)(SEQ ID NO: 6) complexed with native TRX, or T-TXNIP(C36S/C49S/C120S/C170S/C205S/C267S) complexed with TRX(C73A) were used. Both of them contain intermolecular disulfide bonds between TXNIP Cys247 and TRX Cys32 and intramolecular disulfide bonds between TXNIP Cys63 and Cys190. Treatment of TRX-T-TXNIP with H2O2 resulted in dissociation of the proteins in a dose-dependent manner (
Taken together, under normoxic conditions, TXNIP binds to TRX through an intermolecular disulfide bond and inhibits TRX activity, whereas in response to oxidative stress, ROS increases to disrupt the intermolecular disulfide bond between TRX and TXNIP. Therefore, high levels of ROS may cause the intermolecular disulfide to undergo further oxidation, leading to the formation of thiosulfinates. Such intermediates may react readily with any available thiol (e.g. TRX Cys35) to form disulfide bonds (e.g. between TRX Cys32 and Cys35) and sulfenic acid, which in turn, rapidly react with other thiol groups to form other disulfide bonds and water. Consequently, TXNIP is dissociated from TRX. Meanwhile, the ROS may trigger antioxidant pathways, which would then utilize the TRX system, comprising TRX reductase and NADPH, to restore a reducing environment, together with other antioxidant systems. This would lead to a reduction of the TXNIP interdomain disulfide bond between Cys63 and Cys190, making Cys63 available to form an interprotomer disulfide linkage with the Cys247 of another TXNIP molecule. TRX may interact through its active cysteines with the TXNIP interprotomer disulfide bond between Cys63 and Cys247, which would perturb the interprotomer interaction between TXNIP molecules and leave Cys63 orphaned and reactive. Consequently, Cys63 would couple with the C-terminal Cys190, producing S-shape from w-shape. This structure would eventually facilitate the formation of a stable interaction interface between TRX and TXNIP through TRX Cys32 and TXNIP Cys247 (
Based on the above description, it will be understood by those skilled in the art that the present invention may be implemented in a different specific form without changing the technical spirit or essential characteristics thereof. Therefore, it should be understood that the above embodiment is not limitative, but illustrative in all aspects. The scope of the invention is defined by the appended claims rather than by the description preceding them, and therefore all changes and modifications that fall within metes and bounds of the claims, or equivalents of such metes and bounds are therefore intended to be embraced by the claims.
Since TXNIP protein is a protein that regulates TRX activity through interaction with TRX protein, thereby exhibiting various physiological activities such as regulation of cell proliferation, blood glucose level, etc., a crystal of the TRX and TXNIP protein complex provided in the present invention, a crystallization method and a three-dimensional structure thereof can be usefully applied to development of new drugs for the treatment or diagnosis of diseases such as cancer or diabetes, which are associated with interaction between TRX and TXNIP proteins.
Number | Date | Country | Kind |
---|---|---|---|
10-2012-0076310 | Jul 2012 | KR | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/KR2013/006286 | 7/12/2013 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2014/011003 | 1/16/2014 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
20050143402 | Cheetham | Jun 2005 | A1 |
20110097317 | Berk | Apr 2011 | A1 |
20120058105 | Ng | Mar 2012 | A1 |
Entry |
---|
Wiencek, J. M. Ann. Rev. Biomed. Eng. 1999, 1, 505-534. |
Fould et al., “Mutagenic analysis in a pure molecular system shows that thioredoxin-interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin,” Protein Science, 21: 1323-1333 (2012). |
Polekhina et al., “Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein,” Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 67: 613-617 (2011). |
Yoshihara et al., “Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity,” Nature Communications, 1: 1-12 (2010). |
Kalnine et al., “Homo sapiens thioredoxin [synthetic construct],” Protein—NCBI GenBank accession No. AAP36296 (2003). |
Powis et al., “Thioredoxin signaling as a target for cancer therapy,” Current Opinion in Pharmacology, 7: 392-397 (2007). |
Mukherjee et al., “The thioredoxin system: a key target in tumour and endothelial cells,” British Institute of Radiology (2014) abstract only. |
Schulze et al., “Hyperglycemia Promotes Oxidative Stress through Inhibition of Thioredoxin Function by Thioredoxin-interacting Protein,” Journal of Biological Chemistry, 279: 30369-30374 (2004). |
Dunn et al., “The Emerging Role of the Thioredoxin System in Angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, 30: 2089-2098 (2010). |
Spindel et al., “Thioredoxin Interacting Protein: Redox Dependent and Independent Regulatory Mechanisms,” Antioxidants & Redox Signaling, 16: 587-596 (2012). |
Shin et al., “hnRNP G elicits tumor suppressive activity in part by upregulating the expression of Txnip,” Biochemical and Biophysical Research Communications, 372: 880-885 (2008). |
Sheth et al., “Hepatocellular carcinoma in Txnip-deficient mice,” Oncogene, 25: 3528-3536 (2006). |
Matsuoka et al., “Involvement of thioredoxin-binding protein 2 in the antitumor activity of CD437,” Cancer Science, 99: 2485-2490 (2008). |
Muoio, “TXNIP Links Redox Circuitry to Glucose Control,” Cell Metabolism, 5: 412-414 (2007). |
Minn et al., “Thioredoxin-Interacting Protein Is Stimulated by Glucose through a Carbohydrate Response Element and Induces B-Cell Apoptosis,” Endocrinology, 146: 2397-2405 (2005). |
Stoltzman et al., “Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression,” Proceedings of the National Academy of Sciences, 105: 5912-6917 (2008). |
Chen et al., “Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes,” The FASEB Journal, 322: 3581-3594 (2008). |
Parikh et al., “TXNIP Regulates Peripheral Glucose Metabolism in Humans,” PLoS Medicine, 4: 0868-0879, e158 (2007). |
International Search Report issued in corresponding International Patent Application No. PCT/KR2013/006286 dated Oct. 15, 2013. |
Number | Date | Country | |
---|---|---|---|
20150284436 A1 | Oct 2015 | US |